Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Buy Salesforce (CRM) Stock on the Dip Before Q1 Earnings?

Published 05/20/2021, 07:15 AM
Updated 07/09/2023, 06:31 AM

The cloud-based business software firm is one of the last big names in tech left to report its first quarter earnings results, alongside the likes of Nvidia NVDA. Salesforce (NYSE:CRM) CRM stock has moved roughly sideways in 2021 to lag the tech space and the S&P 500’s 11 climb even though it is coming off a record-breaking year.

So let’s look at Salesforce stock ahead of its Q1 FY22 financial release on Thursday, May 27 to see if it might be worth buying on the dip.

Growth Basics

Salesforce helped create the software-as-a-service industry that has been booming for years. CRM’s cloud-based customer relationship management services offer clients a range of tools and applications to help run everything from sales and e-commerce to marketing and analytics. And the pandemic highlighted the importance of the space.

The company posted record sales last year, with revenue up 24% to $21.3 billion, to crack $20 billion for the first time ever. CRM also raised its guidance to help showcase that SaaS is ready to keep growing as businesses of all shapes and sizes adapt to the digital age and rely on various software to help them do just about everything.

Zacks estimates call for Salesforce’s fiscal 2022 revenue to climb another 21% to $25.7 billion, with FY23 projected to jump 19% higher to come in at $30.5 billion. Meanwhile, its adjusted FY22 earnings are projected to fall 30% to $3.44 a share, with FY23 then set to bounce 18% above our current-year estimate.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The company boasts a solid history of quarterly earnings beats, including a 73% average in the trailing four periods. Yet CRM’s earnings revisions have remained stagnant recently to help it land a Zacks Rank #3 (Hold), alongside a “D” grade for Momentum in our Style Scores system.

What Else

Salesforce made a splash in December when it announced its $28 billion deal—which is the second-largest in software history—to buy Slack WORK. Some Wall Street analysts think Salesforce overpaid for the work-focused communication firm. But clearly CRM’s executive team, who paid $15 billion in 2019 for data-analytics platform Tableau, believe Slack will prove vital in the digital-heavy business world.

The definitive agreement to acquire Slack is a bet that the business world is moving toward work from anywhere mode. The new hybrid environment puts an emphasis on non-email communication and should help Salesforce compete against Microsoft MSFT, Zoom Video ZM, and others.

Despite all of the positives and its standing in the booming and vital cloud software industry, Salesforce stock has lagged the broader Zacks tech sector over the last three years. The stock closed regular trading Thursday at around $224 a share, or about 20% below its September 2020 records. And it has failed to regain any real momentum so far this year.

CRM sits at around a 53 in terms of the Relative Strength Index, which puts it right near neutral levels. On the valuation side, Salesforce is trading in line with its industry at 7.5X forward 12-month sales. But it still trades at sky-high valuations in terms of forward earnings and it does not yet pay a dividend as it focuses on growth.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Bottom Line

The Nasdaq jumped on Thursday to right near its 50-day moving average, as bullish tech investors keep buying the dips.

Some might want to wait for Salesforce to report before diving into the underperforming stock to see how Wall Street reacts. That said, 17 of the 23 brokerage recommendations Zacks has for CRM are “Strong Buys,” with the other at “Holds.”

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Microsoft Corporation (NASDAQ:MSFT): Free Stock Analysis Report

NVIDIA Corporation (NASDAQ:NVDA): Free Stock Analysis Report

salesforce.com, inc. (CRM): Free Stock Analysis Report

Zoom Video Communications, Inc. (NASDAQ:ZM): Free Stock Analysis Report

Slack Technologies, Inc. (NYSE:WORK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.